Offer To Purchase For Cash - ENDO PHARMACEUTICALS HOLDINGS INC - 12-5-2001

Document Sample
Offer To Purchase For Cash - ENDO PHARMACEUTICALS HOLDINGS INC - 12-5-2001 Powered By Docstoc
					OFFER TO PURCHASE FOR CASH UP TO 13,500,000 CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OUTSTANDING CLASS B NON-TRANSFERABLE WARRANTS OF ENDO PHARMACEUTICALS HOLDINGS INC. AT $0.75 NET PER WARRANT BY ENDO PHARMACEUTICALS HOLDINGS INC. December 5, 2001 TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES: Endo Pharmaceuticals Holdings Inc., a Delaware corporation (the "Company"), is offering to purchase up to 13,500,000 outstanding Class A Transferable Warrants (the "Class A Warrants") and any and all outstanding Class B Non-Transferable Warrants (the "Class B Warrants" and, collectively with the Class A Warrants, the "Warrants") of the Company at a purchase price of $0.75 per Warrant, net to the seller in cash (such amount, or any greater amount per Warrant paid pursuant to the Offer, being referred to as the "Offer Price"), without interest thereon, upon the terms and subject to the conditions described in the Offer to Purchase and the Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the "Offer"). We are requesting that you contact your clients for whom you hold Warrants regarding the Offer. For your information and for forwarding to your clients for whom you hold Warrants registered in your name or in the name of your nominee, or who hold Warrants registered in their own names, we are enclosing the following documents: 1. Offer to Purchase, dated December 5, 2001 2. The Letter of Transmittal for your use and for the information of your clients; 3. A Notice of Guaranteed Delivery to be used to accept the Offer if certificates for Warrants are not immediately available or time will not permit all required documents to reach the Depositary prior to the Expiration Date (as defined below) or if the procedure for book-entry transfer cannot be completed on a timely basis; and 4. A form of letter which may be sent to your clients for whose account you hold Warrants registered in your name or the name of your nominee, with space provided for obtaining such clients' instructions with regard to the Offer. YOUR PROMPT ACTION IS REQUESTED. THE OFFER WILL EXPIRE AT MIDNIGHT, NEW YORK CITY TIME, ON JANUARY 14, 2002, UNLESS EXTENDED BY US (THE "EXPIRATION DATE"). WARRANTS TENDERED PURSUANT TO THE OFFER MAY BE WITHDRAWN AT ANY TIME BEFORE THE EXPIRATION DATE. To participate in the Offer, a duly executed and properly completed Letter of Transmittal (or facsimile thereof or Agent's Message in lieu thereof), with any required signature guarantees and any other required documents, should be sent to the Depositary and certificates representing the Warrants, or, in the case of uncertificated Class A Warrants, a timely confirmation of a book-entry transfer of such Class A Warrants, should be delivered to the Depositary, all in accordance with the instructions set forth in the Letter of Transmittal and the Offer to Purchase.

If a registered holder of Warrants desires to tender, but such Warrants are not immediately available, or time will not permit such holder's Warrants or other required documents to reach the Depositary before the Expiration Date, or the procedure for book-entry transfer cannot be completed on a timely basis, a tender may be effected by following the guaranteed delivery procedures described in the Offer to Purchase under "The Offer -Guaranteed Delivery Procedures." The Company will, upon request, reimburse brokers, dealers, commercial banks and trust companies for reasonable and necessary costs and expenses incurred by them in forwarding the Offer to Purchase and the related documents to the beneficial owners of Warrants held by them as nominee or in a fiduciary capacity. The Company will not make any payments to brokers, dealers, or others soliciting acceptances of the Offer. Any inquiries you may have with respect to the Offer, or requests for additional copies of the enclosed materials, should be directed to Mackenzie Partners, Inc., the Information Agent for the Offer, at its address and telephone number set forth on the front of the Letter of Transmittal. Very truly yours, Endo Pharmaceuticals Holdings Inc. NOTHING HEREIN OR IN THE ENCLOSED DOCUMENTS SHALL CONSTITUTE YOU OR ANY PERSON AS AN AGENT OF THE COMPANY, THE DEPOSITARY OR THE INFORMATION AGENT, OR AUTHORIZE YOU OR ANY OTHER PERSON TO USE ANY DOCUMENT OR MAKE ANY STATEMENTS ON BEHALF OF ANY OF THEM WITH RESPECT TO THE OFFER, EXCEPT FOR STATEMENTS EXPRESSLY MADE IN THE OFFER TO PURCHASE OR THE LETTER OF TRANSMITTAL. Enclosures 2

OFFER TO PURCHASE FOR CASH UP TO 13,500,000 CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OUTSTANDING CLASS B NON-TRANSFERABLE WARRANTS OF ENDO PHARMACEUTICALS HOLDINGS INC. AT $0.75 NET PER WARRANT BY ENDO PHARMACEUTICALS HOLDINGS INC. December 5, 2001 TO OUR CLIENTS: Enclosed for your consideration is an Offer to Purchase, dated December 5, 2001 (the "Offer to Purchase"), and the related letter of transmittal (the "Letter of Transmittal"), relating to the offer by Endo Pharmaceutical Holdings, Inc., a Delaware corporation (the "Company"), to purchase up to 13,500,000 of the outstanding Class A Transferable Warrants (the "Class A Warrants") and any and all of the outstanding Class B Non-Transferable Warrants (the "Class B Warrants" and, collectively with the Class A Warrants, the "Warrants") of the Company at a purchase price of $0.75 per Warrant, net to the seller in cash (such amount, or any greater amount per Warrant paid pursuant to the Offer, being referred to as the "Offer Price"), without interest thereon, upon the terms and subject to the conditions described in the Offer to Purchase and the Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the "Offer"). WE ARE THE HOLDER OF RECORD (DIRECTLY OR INDIRECTLY) FOR CLASS A WARRANTS HELD IN YOUR ACCOUNT.

OFFER TO PURCHASE FOR CASH UP TO 13,500,000 CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OUTSTANDING CLASS B NON-TRANSFERABLE WARRANTS OF ENDO PHARMACEUTICALS HOLDINGS INC. AT $0.75 NET PER WARRANT BY ENDO PHARMACEUTICALS HOLDINGS INC. December 5, 2001 TO OUR CLIENTS: Enclosed for your consideration is an Offer to Purchase, dated December 5, 2001 (the "Offer to Purchase"), and the related letter of transmittal (the "Letter of Transmittal"), relating to the offer by Endo Pharmaceutical Holdings, Inc., a Delaware corporation (the "Company"), to purchase up to 13,500,000 of the outstanding Class A Transferable Warrants (the "Class A Warrants") and any and all of the outstanding Class B Non-Transferable Warrants (the "Class B Warrants" and, collectively with the Class A Warrants, the "Warrants") of the Company at a purchase price of $0.75 per Warrant, net to the seller in cash (such amount, or any greater amount per Warrant paid pursuant to the Offer, being referred to as the "Offer Price"), without interest thereon, upon the terms and subject to the conditions described in the Offer to Purchase and the Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the "Offer"). WE ARE THE HOLDER OF RECORD (DIRECTLY OR INDIRECTLY) FOR CLASS A WARRANTS HELD IN YOUR ACCOUNT. A TENDER OF SUCH CLASS A WARRANTS CAN ONLY BE MADE BY US AS THE HOLDER OF RECORD OR BY OUR NOMINEES AS THE HOLDER OF RECORD AND PURSUANT TO YOUR INSTRUCTIONS. THE ENCLOSED LETTER OF TRANSMITTAL IS FURNISHED TO YOU FOR YOUR INFORMATION ONLY AND CANNOT BE USED BY YOU TO TENDER WARRANTS HELD BY US FOR YOU IN YOUR ACCOUNT. We request instructions as to whether you wish us to tender on your behalf any or all of the Class A Warrants held by us for your account, pursuant to the terms and conditions set forth in the Offer. The Offer will expire at 12:00 midnight., New York City time, on January 14, 2002 (the "Expiration Date"), unless extended by the Company. Any Warrants tendered pursuant to the Offer may be withdrawn at any time before the Expiration Date. Your attention is directed to the following: 1. The Offer Price is $0.75 per Warrant, net to you in cash without interest. 2. The Offer is being made for any and all outstanding Warrants. 3. The Board of Directors of the Company has not made any recommendation to you as to whether you should tender your Warrants pursuant to the Offer. 4. THE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON JANUARY 14, 2002, (THE "EXPIRATION DATE"), UNLESS EXTENDED BY THE COMPANY. ANY WARRANTS TENDERED PURSUANT TO THE OFFER MAY BE WITHDRAWN AT ANY TIME BEFORE THE EXPIRATION DATE. 5. You will not be obligated to pay brokerage fees or commissions or, except as otherwise provided in Instruction 5 of the Letter of Transmittal, transfer taxes with respect to the purchase of Warrants by the Company pursuant to the Offer.

If you wish to have us tender any or all of your Class A Warrants, please so instruct us by completing, executing and returning the instruction form set forth on the opposite side of this letter. An envelope in which to return your instructions to us is enclosed. If you authorize the tender of your Warrants, all such Warrants shall be tendered unless otherwise specified in your instructions. YOUR INSTRUCTIONS SHOULD BE FORWARDED TO US AS PROMPTLY AS POSSIBLE IN ORDER TO PERMIT US TO TENDER THE CLASS A WARRANTS ON YOUR BEHALF IN ACCORDANCE WITH THE PROVISIONS OF THE OFFER. The instructions set forth on the opposite side of this letter will be valid only for the Warrants held by us in your account. IF YOU ARE THE HOLDER OF ANY CLASS B WARRANTS, OR ANY OTHER CLASS A WARRANTS NOT HELD OF RECORD BY US, AND YOU WISH TO TENDER ANY OF SUCH WARRANTS PURSUANT TO THE OFFER, YOU WILL NEED TO SEPARATELY TENDER SUCH WARRANTS IN ACCORDANCE WITH THE PROCEDURES OUTLINED IN THE OFFER TO PURCHASE AND THE ACCOMPANYING LETTER OF TRANSMITTAL. 2

INSTRUCTIONS WITH RESPECT TO THE OFFER TO PURCHASE FOR CASH UP TO 13,500,000 OUTSTANDING CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OUTSTANDING CLASS B NON-TRANSFERABLE WARRANTS OF ENDO PHARMACEUTICALS HOLDINGS INC. The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase, dated December 5, 2001 (the "Offer to Purchase"), and the related Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the "Offer") relating to the offer by Endo Pharmaceutical Holdings Inc., a Delaware corporation (the "Company"), to purchase up to 13,500,000 of the outstanding Class A Transferable Warrants (the "Class A Warrants") and any and all outstanding Class B Non-Transferable Warrants of the Company (the "Class B Warrants" and, collectively with the Class A Warrants, the "Warrants") at a purchase price of $0.75 per Warrant, net to the seller in cash (such amount, or any greater amount per Share paid pursuant to the Offer, being referred to as the "Offer Price"), without interest thereon, upon the terms and subject to the conditions described in the Offer to Purchase and the Letter of Transmittal. This will instruct you to tender the Class A Warrants held by you for the account of the undersigned, upon and subject to the terms and conditions set forth in the Offer to Purchase and the related Letter of Transmittal. Dated: NUMBER OF CLASS A WARRANTS TO BE TENDERED*: CLASS A WARRANTS SIGNATURE (PLEASE TYPE OR PRINT NAME(S))

(PLEASE TYPE OR PRINT NAME(S))

(AREA CODE AND TEL. NO.)

If you wish to have us tender any or all of your Class A Warrants, please so instruct us by completing, executing and returning the instruction form set forth on the opposite side of this letter. An envelope in which to return your instructions to us is enclosed. If you authorize the tender of your Warrants, all such Warrants shall be tendered unless otherwise specified in your instructions. YOUR INSTRUCTIONS SHOULD BE FORWARDED TO US AS PROMPTLY AS POSSIBLE IN ORDER TO PERMIT US TO TENDER THE CLASS A WARRANTS ON YOUR BEHALF IN ACCORDANCE WITH THE PROVISIONS OF THE OFFER. The instructions set forth on the opposite side of this letter will be valid only for the Warrants held by us in your account. IF YOU ARE THE HOLDER OF ANY CLASS B WARRANTS, OR ANY OTHER CLASS A WARRANTS NOT HELD OF RECORD BY US, AND YOU WISH TO TENDER ANY OF SUCH WARRANTS PURSUANT TO THE OFFER, YOU WILL NEED TO SEPARATELY TENDER SUCH WARRANTS IN ACCORDANCE WITH THE PROCEDURES OUTLINED IN THE OFFER TO PURCHASE AND THE ACCOMPANYING LETTER OF TRANSMITTAL. 2

INSTRUCTIONS WITH RESPECT TO THE OFFER TO PURCHASE FOR CASH UP TO 13,500,000 OUTSTANDING CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OUTSTANDING CLASS B NON-TRANSFERABLE WARRANTS OF ENDO PHARMACEUTICALS HOLDINGS INC. The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase, dated December 5, 2001 (the "Offer to Purchase"), and the related Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the "Offer") relating to the offer by Endo Pharmaceutical Holdings Inc., a Delaware corporation (the "Company"), to purchase up to 13,500,000 of the outstanding Class A Transferable Warrants (the "Class A Warrants") and any and all outstanding Class B Non-Transferable Warrants of the Company (the "Class B Warrants" and, collectively with the Class A Warrants, the "Warrants") at a purchase price of $0.75 per Warrant, net to the seller in cash (such amount, or any greater amount per Share paid pursuant to the Offer, being referred to as the "Offer Price"), without interest thereon, upon the terms and subject to the conditions described in the Offer to Purchase and the Letter of Transmittal. This will instruct you to tender the Class A Warrants held by you for the account of the undersigned, upon and subject to the terms and conditions set forth in the Offer to Purchase and the related Letter of Transmittal. Dated: NUMBER OF CLASS A WARRANTS TO BE TENDERED*: CLASS A WARRANTS SIGNATURE (PLEASE TYPE OR PRINT NAME(S))

(PLEASE TYPE OR PRINT NAME(S))

(AREA CODE AND TEL. NO.)

INSTRUCTIONS WITH RESPECT TO THE OFFER TO PURCHASE FOR CASH UP TO 13,500,000 OUTSTANDING CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OUTSTANDING CLASS B NON-TRANSFERABLE WARRANTS OF ENDO PHARMACEUTICALS HOLDINGS INC. The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase, dated December 5, 2001 (the "Offer to Purchase"), and the related Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the "Offer") relating to the offer by Endo Pharmaceutical Holdings Inc., a Delaware corporation (the "Company"), to purchase up to 13,500,000 of the outstanding Class A Transferable Warrants (the "Class A Warrants") and any and all outstanding Class B Non-Transferable Warrants of the Company (the "Class B Warrants" and, collectively with the Class A Warrants, the "Warrants") at a purchase price of $0.75 per Warrant, net to the seller in cash (such amount, or any greater amount per Share paid pursuant to the Offer, being referred to as the "Offer Price"), without interest thereon, upon the terms and subject to the conditions described in the Offer to Purchase and the Letter of Transmittal. This will instruct you to tender the Class A Warrants held by you for the account of the undersigned, upon and subject to the terms and conditions set forth in the Offer to Purchase and the related Letter of Transmittal. Dated: NUMBER OF CLASS A WARRANTS TO BE TENDERED*: CLASS A WARRANTS SIGNATURE (PLEASE TYPE OR PRINT NAME(S))

(PLEASE TYPE OR PRINT NAME(S))

(AREA CODE AND TEL. NO.) (TAX IDENTIFICATION OR SOCIAL SECURITY NO.) * None of the Warrants held by us for your account will be tendered unless we receive written instructions from you to do so. Unless a specific contrary instruction is given in the space provided, your signature(s) hereon shall constitute an instruction to us to tender all the Warrants held by us for your account.

FOR IMMEDIATE RELEASE CONTACT: ROBERT SIEGFRIED/JEREMY FIELDING Kekst and Company 212-521-4800

FOR IMMEDIATE RELEASE CONTACT: ROBERT SIEGFRIED/JEREMY FIELDING Kekst and Company 212-521-4800 ENDO PHARMACEUTICALS HOLDINGS INC. ANNOUNCES TENDER OFFER FOR UP TO 13, 500,000 OF ITS CLASS A TRANSFERABLE WARRANTS AND ANY AND ALL OF ITS CLASS B NON-TRANSFERABLE WARRANTS AT $0.75 NET PER WARRANT Chadds Ford, Pennsylvania, December 5, 2001-- Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) announced today that it will commence a tender offer to purchase up to 13,500,000 of its outstanding Class A Transferable Warrants (Nasdaq: ENDPW) and any and all of its outstanding Class B Non-Transferable Warrants. The Company is offering to purchase the Warrants at a purchase price of $0.75 per Warrant. The Company will use cash on hand to finance the purchase of tendered Warrants. The Company is offering to purchase approximately 77% of its outstanding Class A Warrants and 100% of its Class B Warrants pursuant to the offer. As of December 3, 2001, there were 17,576,424 Class A Warrants outstanding and 26,975 Class B Warrants outstanding. The Warrants that are the subject of the offer were initially issued by the Company in July 2000 to stockholders of Algos Pharmaceutical Corporation in connection with the acquisition of Algos by the Company. The Warrants will become exercisable to purchase a specified amount of common stock of the Company at a price of $0.01 per share if the Company obtains U.S. Food and Drug Administration (the "FDA") approval of its development-stage drug MorphiDex(R) on or before March 31, 2003. The terms of the Class A Warrants and the Class B Warrants are identical, except that the Class B Warrants are not freely transferable and have not been listed on the Nasdaq National Market. The offer is scheduled to expire at 12:00 midnight, New York City time, on January 14, 2002, unless the Company elects to extend the offer. The offer is subject to various conditions described in the Offer to Purchase. A principal purpose of the offer is to benefit the holders of the Company's common stock by providing protection against the dilutive effect of the Warrants should they become exercisable. In addition, the tender will afford Warrant holders the ability to obtain a premium to the current market price for the Class A Warrants that are listed on the Nasdaq National Market, and, in the case of holders of Class B Warrants, to obtain liquidity for their non-transferable Warrants. The Company also stated that it believes that the Offer will simplify the ability of the Company and third parties to value the Company on a per-share basis by reducing the impact of, and uncertainty created by, the outstanding Warrants. The Company's board of directors has approved, and authorized the Company to conduct, the offer, although it is making no recommendation as to whether any holder of Warrants should tender any or all of its Warrants pursuant to the offer. Each holder must make his, her, or its own decision 1

whether to tender Warrants and, if so, how many Warrants to tender. Messrs. Hyatt, Kimmel and Lyle, former Algos stockholders who are members of the Company's Board of Directors, may be deemed to beneficially own in the aggregate approximately 24% of the issued and outstanding Class A Warrants. Such individuals have indicated that they do not intend to tender any such Warrants in the offer, other than approximately 55,000 Class A Warrants over which Mr. Kimmel, in his capacity as trustee of a trust for the benefit of Mr. Hyatt's children, exercises shared dispositive and voting power and with respect to which he and his family members disclaim beneficial ownership. This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any Warrants of Endo Pharmaceuticals Holdings Inc. The offer is being made solely by the Offer to Purchase and

whether to tender Warrants and, if so, how many Warrants to tender. Messrs. Hyatt, Kimmel and Lyle, former Algos stockholders who are members of the Company's Board of Directors, may be deemed to beneficially own in the aggregate approximately 24% of the issued and outstanding Class A Warrants. Such individuals have indicated that they do not intend to tender any such Warrants in the offer, other than approximately 55,000 Class A Warrants over which Mr. Kimmel, in his capacity as trustee of a trust for the benefit of Mr. Hyatt's children, exercises shared dispositive and voting power and with respect to which he and his family members disclaim beneficial ownership. This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any Warrants of Endo Pharmaceuticals Holdings Inc. The offer is being made solely by the Offer to Purchase and the related Letter of Transmittal. Investors are urged to read the Company's Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission (the "SEC") in connection with the tender offer, which includes as exhibits the Offer to Purchase and the related Letter of Transmittal, as well as any amendments or supplements to the Statement when they become available, because they contain important information. Each of these documents has been or will be filed with the SEC, and investors may obtain them for free from the SEC at the SEC's website (www.sec.gov) or from MacKenzie Partners, Inc., the information agent for the tender offer, by directing such request to: MacKenzie Partners, Inc., 156 Fifth Avenue, New York, NY, 10010, telephone (212) 929-5500 or (800) 322-2885. ABOUT ENDO Endo is a fully integrated specialty pharmaceutical company with market leadership in pain management products. The company researches, develops, produces and markets a broad product offering of both branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike. This and past press releases of Endo Pharmaceuticals Holdings Inc. are available at Endo's Web site at http://www.endo.com. This release may include information that could constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements may involve risk and uncertainties that could cause actual results to differ materially from any future results encompassed within the forward-looking statements. Factors that could cause or contribute to such differences include those matters disclosed in the Company's Securities and Exchange Commission filings. ************ 2

GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 GUIDELINES FOR DETERMINING THE PROPER IDENTIFICATION NUMBER TO GIVE THE PAYOR. -- Social Security numbers have nine digits separated by two hyphens, e.g., 000-00-0000. Employer identification numbers have nine digits separated by only one hyphen, e.g., 000000000. The table below will help determine the number to give the payor.
-----------------------------------------------------------GIVE THE NAME* AND SOCIAL SECURITY FOR THIS TYPE OF ACCOUNT: NUMBER OF ------------------------------------------------------------1. Individual The individual 2. Two or more individuals (joint The actual owner of account) the account or, if combined funds, the first individual on the account(1) 3. Custodian account of a minor The minor(2) (Uniform Gift to Minors Act) 4. a. The usual revocable savings The grantortrust (grantor is also trustee) trustee(1) b. So-called "trust" account that The actual owner(1)

GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 GUIDELINES FOR DETERMINING THE PROPER IDENTIFICATION NUMBER TO GIVE THE PAYOR. -- Social Security numbers have nine digits separated by two hyphens, e.g., 000-00-0000. Employer identification numbers have nine digits separated by only one hyphen, e.g., 000000000. The table below will help determine the number to give the payor.
-----------------------------------------------------------GIVE THE NAME* AND SOCIAL SECURITY FOR THIS TYPE OF ACCOUNT: NUMBER OF ------------------------------------------------------------1. Individual The individual 2. Two or more individuals (joint The actual owner of account) the account or, if combined funds, the first individual on the account(1) 3. Custodian account of a minor The minor(2) (Uniform Gift to Minors Act) 4. a. The usual revocable savings The grantortrust (grantor is also trustee) trustee(1) b. So-called "trust" account that The actual owner(1) is not a legal or valid trust under state law 5. Sole proprietorship The owner(3) ------------------------------------------------------------

-----------------------------------------------------------GIVE THE NAME AND EMPLOYER IDENTIFICATION FOR THIS TYPE OF ACCOUNT: NUMBER OF ------------------------------------------------------------6. A valid trust, estate, or pension Legal entity(4) trust 7. Corporate The corporation 8. Association, club, religious, The organization charitable, educational or other tax-exempt organization 9. Partnership The partnership 10. A broker or registered nominee The broker or nominee 11. Account with the Department of The public entity Agriculture in the name of a public entity (such as a state or local government, school district, or prison) that receives agricultural program payments ------------------------------------------------------------

* If you are an individual, you must generally enter the name shown on your social security card. However, if you have changed your last name, for instance, due to marriage, without informing the Social Security Administration of the name change, enter your first name, the last name shown on your social security card, and your new last name. (1) List first and circle the name of the person whose number you furnish. If only one person on a joint account has a social security number, that person's number must be furnished. (2) Circle the minor's name and furnish the minor's social security number. (3) You must show your individual name and may enter either your social security number or employee identification number.

(4) List first and circle the name of the legal trust, estate or pension trust. (Do not furnish the TIN of the personal representative or trustee unless the legal entity itself is not designated in the account title.) NOTE: If no name is circled when more than one name is listed, the number will be considered to be that of the first name listed.